Literature DB >> 15579916

Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance.

D Marisavljević1, Z Rolović, V Cemerikić, D Bosković, M Colović.   

Abstract

In a retrospective study of 236 patients with primary myelodysplastic syndromes (MDS), 130 cases (55.1%) revealed myelofibrosis in bone marrow biopsies. It was observed that fibrosis mostly occurs focally or patchy, and collagen deposits were found very rarely (only four patients). The histopathology of bone marrow biopsies revealed several differences between fibrotic and non-fibrotic MDS: cellularity is significantly higher, dysmegakaryopoiesis is more pronounced, plasmocytes and mast cells are more often increased, and disturbance of marrow topography (particularly of the MK- and G-line) can be found more frequently in MDS with myelofibrosis. Reticulin fibrosis occurred in all subtypes of MDS; however, there was a higher incidence in chronic myelomonocytic leukemia. The frequency of abnormal growth of GM-progenitors was significantly higher in the MDS cases with myelofibrosis, compared to the cases without fibrosis. Clinical data showed significantly higher WBC, more frequent presence of immature granulocytes, and higher percentage of myeloblasts in peripheral blood and bone marrow in MDS with myelofibrosis compared to cases without myelofibrosis. Life expectancy was reduced to 13 mo, compared with 35 mo in MDS without fibrosis (p=0.00055). Time to leukemic transformation was 32 mo in MDS with fibrosis, compared with >56 mo in MDS without fibrosis (p=0.015). Myelofibrosis therefore seems to herald a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579916     DOI: 10.1385/MO:21:4:325

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes.

Authors:  D Marisavljević; Z Rolović; D Sefer; N Basara; D Ilić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients.

Authors:  H Maschek; A Georgii; V Kaloutsi; M Werner; K Bandecar; M G Kressel; H Choritz; M Freund; D Hufnagl
Journal:  Eur J Haematol       Date:  1992-04       Impact factor: 2.997

3.  Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A.

Authors:  N N Iscove; F Sieber; K H Winterhalter
Journal:  J Cell Physiol       Date:  1974-04       Impact factor: 6.384

4.  Myelodysplastic syndromes: a scoring system with prognostic significance.

Authors:  G J Mufti; J R Stevens; D G Oscier; T J Hamblin; D Machin
Journal:  Br J Haematol       Date:  1985-03       Impact factor: 6.998

5.  Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears.

Authors:  G Tricot; C De Wolf-Peeters; B Hendrickx; R L Verwilghen
Journal:  Br J Haematol       Date:  1984-07       Impact factor: 6.998

Review 6.  Acute ("malignant") myelosclerosis.

Authors:  R M Bearman; G A Pangalis; H Rappaport
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

7.  Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases.

Authors:  S D Michels; R W McKenna; D C Arthur; R D Brunning
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

8.  Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis.

Authors:  R Raymakers; F Preijers; J Boezeman; E Rutten; T De Witte
Journal:  Leuk Lymphoma       Date:  1994-06

9.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.

Authors:  G F Sanz; M A Sanz; T Vallespí; M C Cañizo; M Torrabadella; S García; D Irriguible; J F San Miguel
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

10.  Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors.

Authors:  A Ríos; M C Cañizo; M A Sanz; T Vallespí; G Sanz; M Torrabadella; F Gomis; C Ruiz; J F San Miguel
Journal:  Br J Haematol       Date:  1990-05       Impact factor: 6.998

View more
  9 in total

1.  Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Nicolaus Kröger; Tatjana Zabelina; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Rodrigo Martino; Zi Yi Lim; Francesco Onida; Christoph Schmid; Laurent Garderet; Marie Robin; Michael van Gelder; Reinhard Marks; Argiris Symeonidis; Guido Kobbe; Theo de Witte
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Hypocellular myelodysplastic syndrome with myelofibrosis in acute myeloid leukemia transformation: A case report.

Authors:  Kui Song; Xiaojun Xu; Min Li
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

3.  TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.

Authors:  Sanam Loghavi; Alyaa Al-Ibraheemi; Zhuang Zuo; Guillermo Garcia-Manero; Mariko Yabe; Sa A Wang; Hagop M Kantarjian; Cameron C Yin; Roberto N Miranda; Raja Luthra; L Jeffrey Medeiros; Carlos E Bueso-Ramos; Joseph D Khoury
Journal:  Br J Haematol       Date:  2015-06-30       Impact factor: 6.998

4.  Platelet derived growth factor receptor-beta (PDGFRβ) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis.

Authors:  Judit Bedekovics; Attila Kiss; Lívia Beke; Katalin Károlyi; Gábor Méhes
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

Review 5.  Transient myelofibrosis with autoimmune pancytopenia: a case report.

Authors:  Tomohei Nakao; Takashi Fukushima; Takashi Shimizu; Toru Nanmoku; Satoshi Fujiyama; Ryoko Nakajima; Fujiko Fukushima; Masayuki Noguchi; Ryo Sumazaki
Journal:  Eur J Pediatr       Date:  2008-11-06       Impact factor: 3.183

6.  Bone marrow hyaluronan and reticulin in patients with malignant disorders.

Authors:  G Sundström; M Hultdin; A Engström-Laurent; I M S Dahl
Journal:  Med Oncol       Date:  2009-06-23       Impact factor: 3.064

Review 7.  Role of the microenvironment in myeloid malignancies.

Authors:  Marie Goulard; Christine Dosquet; Dominique Bonnet
Journal:  Cell Mol Life Sci       Date:  2017-12-08       Impact factor: 9.261

Review 8.  Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.

Authors:  Akriti G Jain; Ling Zhang; John M Bennett; Rami Komrokji
Journal:  Ann Lab Med       Date:  2022-05-01       Impact factor: 3.464

9.  Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Authors:  Fernando Ramos; Cristina Robledo; Francisco Miguel Izquierdo-García; Dimas Suárez-Vilela; Rocío Benito; Marta Fuertes; Andrés Insunza; Eva Barragán; Mónica Del Rey; José María García-Ruiz de Morales; Mar Tormo; Eduardo Salido; Lurdes Zamora; Carmen Pedro; Javier Sánchez-Del-Real; María Díez-Campelo; Consuelo Del Cañizo; Guillermo F Sanz; Jesús María Hernández-Rivas
Journal:  Oncotarget       Date:  2016-05-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.